AGIO
Agios Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $2.21B market cap
Forecast run · Oct 29, 2026Upside rank 1454 of 3,186
Model Signal
ForecastQ Daily Probabilities
27.6%
58.2%
14.5%
Analyst Consensus
Recommendation2.24/5 Buy
Last price$37.00
Price target$41.33
Implied move+11.7%
Analysts29
ForecastQ Portfolios
AGIO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.